NSABP B55 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

June 29, 2018
https://clinicaltrials.gov/ct2/show/NCT02032823
Cancer - Breast
Principal Investigator: Thomas J Doyle, MD
CANCER, BREAST, BREAST CANCER, ADJUVANT, HIGH RISK, BRCA, HER2 NEGATIVE, HER 2 NEGATIVE, HER2, HER 2
Accepting Participants